Ruxolitinib inhibits poly (I:C) and IL-13-induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma

Running title: RUXOLITINIB INHIBITS CCL5 PRODUCTION IN BRONCHIAL EPITHELIUM
Mitsuru Sada1, Masato Watanabe1, Toshiya Inui1, Keitaro Nakamoto1, Aya Hirata1, Masuo Nakamura1, Kojiro Honda1, Takeshi Saraya1, Daisuke Kurai2, Hirokazu Kimura3, Haruyuki Ishii1 & Hajime Takizawa1
1 Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan
2 Department of General Medicine, Division of Infectious Diseases, School of Medicine, Kyorin University, Tokyo, Japan
3 Department of Health Science, Graduate School of Health Science, Gunma Paz University, Gunma, Japan.
Correspondence: Mitsuru SadaPhone: +81(0)-422-47-5511
e-mail:rainbow_orchestra716@yahoo.co.jp
Key Words: CCL5, Eosinophilic asthma, Ruxolitinib, Bronchial epithelium, IL-13